Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Jonasch on the Potential of Immunotherapy for Sarcomatoid RCC

Eric Jonasch, MD
Published: Thursday, Jun 22, 2017



Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the potential of immunotherapy for patients with sarcomatoid renal cell carcinoma (RCC).

Sarcomatoid RCC is a difficult area to treat from an efficacy standpoint, explains Jonasch. Emerging data suggest that immuno-oncology agents might be useful for this patient population.

There are published data demonstrating that PD-L1 expression is higher with sarcomatoid RCC and raises the hypothesis that targeting PD-1/PD-L1 might be beneficial, states Jonasch.
 


Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the potential of immunotherapy for patients with sarcomatoid renal cell carcinoma (RCC).

Sarcomatoid RCC is a difficult area to treat from an efficacy standpoint, explains Jonasch. Emerging data suggest that immuno-oncology agents might be useful for this patient population.

There are published data demonstrating that PD-L1 expression is higher with sarcomatoid RCC and raises the hypothesis that targeting PD-1/PD-L1 might be beneficial, states Jonasch.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x